SnowWorld N.V. — Earnings Release 2009

May 7, 2009

P R E S S R E L E A S E

Lelystad, 7 May 2009

FORNIX PUBLISHES TRADING UPDATE

• Limited decrease in turnover in first four months of 2009 compared to 2008
• Further explanation of dividend pay-out
• Registration and reimbursement issue continues to dominate agenda
• Considerably lower investment in R&D
• Strategic reorientation fully underway

Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI) is publishing a qualitative trading update for the first time today. Fornix posted a limited decrease in turnover in the first four months of 2009 compared to the same period of 2008. While turnover clearly lagged behind in January and February, there was a recovery in March and April.

The dividend with stock option for 2008 was set at € 1.39 per share at Fornix's last Annual General Meeting of Shareholders held on 24 April 2009. A final dividend of € 0.74 per share remained after deduction of the interim dividend of € 0.65 that was paid out in September 2008. The decision was made for the third successive year to pay out the entire profit for the financial year (2008: € 10.3 million) to shareholders in the form of dividend with stock option. This decision was based on the company's strong liquidity position – Fornix is debt-free.

Registration of Oralgen® Grass Pollen

The issue concerning the registration of Oralgen® Grass Pollen and the reimbursement status of the Oralgen® products continue to dominate Fornix's agenda. Despite what Fornix views as the positive outcome of the follow-up study, the results of which were announced in mid-January 2009, the Dutch Medicines Evaluation Board (MEB) ruled in late March 2009 that substantiation of the clinical effect was insufficient. The MEB therefore did not see any reason to revise its previous rejection of the registration application.

Appeal resumed

Fornix disagrees with the view of the MEB. The appeal against the rejection that was previously submitted to the Court in Zwolle in 2007, which had been adjourned, has consequently been resumed. The tentative registration status of Oralgen® Grass Pollen will remain in effect pending the outcome of this appeal.

Due to the increased uncertainty regarding the settlement of the registration application for Oralgen® Grass Pollen, Fornix has decided not to launch any new phase II/III studies into Oralgen® Tree Pollen and Oralgen® House Dust Mite for the time being. The confirmatory study into the long-term efficacy of Oralgen® Grass Pollen announced in August 2008 will be continued for now. Various developments mean that approximately € 3 million less will be invested than was originally budgeted in the Clinical Development Plan.

Reimbursement status

The reimbursement status of the Oralgen® products is also a topic for attention. All these products are currently reimbursed by insurers. The current expectation is that the Dutch Ministry of Health, Welfare and Sport will amend the reimbursement system for allergen products as of 1 July 2009. Registered products will be reimbursed via the Medicine Reimbursement Scheme (MRS). Non-registered products will only be eligible for reimbursement if a registered alternative is not available. Reimbursement limits for allergen products will most likely also be adopted in the short term and this could place pressure on

prices. These changes could lead to Oralgen® Grass Pollen no longer being reimbursed for new patients in light of the fact that a registered alternative is available in the Netherlands. There is currently uncertainty regarding the reimbursement status of the Oralgen® Grass Pollen and Tree Pollen combined preparations.

All existing patients of Fornix will continue to be eligible for reimbursement after 1 July 2009. There is uncertainty with respect to the reimbursement limits and there is a possibility that the turnover of the other Oralgen® products will also decrease. Fornix nonetheless expects to be able to continue to generate a positive cash flow in the years ahead even in the event of a worst case scenario regarding registration and reimbursement.

Strategic reorientation

The unclear situation pertaining to the registration and reimbursement of our core allergen products necessitates an accelerated evaluation of Fornix's strategy. All options regarding both Fornix as a whole and the Allergy and Medical Aids Divisions are consequently being considered as part of this evaluation.

Outlook

Given the uncertain situation relating to the registration of Oralgen® Grass Pollen, particularly with respect to the review of the reimbursement system for allergen products, as stated in the Annual Report published on 12 March 2009, Fornix will not at this time provide a forecast for turnover and profit development in 2009.

_______________________________________________________________________

E N D O F P R E S S R E L E A S E

For further information, please contact: Fornix BioSciences N.V. C.L. Bergman, CEO, Fornix BioSciences N.V. Tel. +31 (0) 320 26 77 99 Website: www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carried out by two divisions, which in turn are made up of operating companies. The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the efficacy of the various products. The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.